MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive prostate cancer and personalise screening strategies.

Researchers have detected microplastics in nearly all prostate cancer tumors examined in a new study. Tumor tissue contained about 2.5 times more plastic than nearby healthy prostate tissue.

The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours or halt their growth.